127
Participants
Start Date
December 31, 2011
Primary Completion Date
April 30, 2015
Study Completion Date
May 17, 2016
Bevacizumab
A vascular endothelial growth factor (VEGF)-specific humanized monoclonal antibody angiogenesis inhibitor. Infusions of 10 mg/kg of bevacizumab will begin on day 1 and will be administered every two weeks until progression of disease or intolerance during the treatment period.
Rindopepimut (CDX-110) with GM-CSF
Rindopepimut/GM-CSF will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM-CSF.
KLH
KLH will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 100 mcg of KLH.
The Long Island Brain Tumor Center at Neurology Surgery, P.C., Commack
Dent Neurologic Institute, 3980 Sheridan Dr, 3rd Flr Clinical Rsch, Amherst
University of Rochester Medical Center, Rochester
University of Pittsburgh Cancer Institute, Pittsburgh
Lehigh Valley Hospital-John and Dorothy Morgan Cancer Center, Allentown
University of Pennsylvania, Philadelphia
The Johns Hopkins Hospital, Baltimore
Wake Forest Baptist Health, Winston-Salem
The Preston Robert Tisch Brain Tumor Center; Duke University Medical Center, Durham
Piedmont Atlanta Hospital, Atlanta
Atlanta Cancer Care, Atlanta
Orlando Health, Inc., Orlando
Memorial Cancer Institute, Hollywood
Tampa General Hospital, Tampa
University of Alabama at Birmingham, Birmingham
Vanderbilt-Ingram Cancer Center, Nashville
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
University of Cincinnati Cancer Institute, Cincinnati
University of Michigan Comprehensive Cancer Center, Ann Arbor
Sparrow Cancer Center, Lansing
John Nasseff Neuroscience Institute, Abbott Northwestern Hospital, 800 e. 28th Str. MR, Minneapolis
NorthShore University Health System, Evanston
Rush University Medical Center, Chicago
Washington University School of Medicine, St Louis
Baylor Research Institute, Dallas
UT Health Science Center, Houston Memorial Hermann Hospital, 6400 Fannin Street, #2800, Houston
Texas Oncology Midtown, Austin
University of Colorado, Denver, Aurora
Utah Cancer Specialists, Salt Lake City
St. Joseph's Hospital and Medical Center / Barrow Neurological Institute, Phoenix
Kaiser Permanente Los Angeles Medical Center, Los Angeles
University of Southern California (USC) Norris Comprehensive Cancer Center, Los Angeles
UC Irvine Chao Family Comprehensive Cancer Center, Orange
University of California San Francisco, San Francisco
Stanford Cancer Institute, Stanford University, Stanford
Legacy Research Institute, Portland
Swedish Neuroscience Research, Seattle
University of Washington Medical Center, Seattle
University of Chicago, Chicago
Dana-Farber Cancer Institute and Mass General Hospital, Boston
New Jersey Neuroscience Institute JFK Medical Center, Edison
Hackensack University Medical Center, Hackensack
Stony Brook University Hospital, Stony Brook
Rhode Island Hospital, Providence
Lead Sponsor
Celldex Therapeutics
INDUSTRY